Innovative Neuromodulation ShiraTronics specializes in minimally invasive neuromodulation systems for treatment of chronic migraine, presenting a unique opportunity to collaborate with healthcare providers seeking advanced therapy options for patients with high unmet needs.

Strong Funding Trajectory With a recent $66 million Series B funding round and prior investments totaling over $85 million, ShiraTronics demonstrates robust financial backing, indicating potential for accelerated product adoption and expansion in clinical settings.

Rapid Clinical Development Having launched its Chronic Migraine System and initiated world-first trial procedures, ShiraTronics is positioned for quick scaling and targeting new markets, offering opportunities for partnership and distribution agreements.

Focus on Market Expansion The company’s recent Australian pilot studies and ongoing clinical trials reveal a strategic push into international markets, opening avenues for global distribution, regulatory support, and sales channels.

Technology Stack Readiness Utilizing a modern web and database infrastructure, ShiraTronics is well-equipped to support scalable deployment, customer engagement, and real-time data collection, facilitating efficient customer onboarding and post-sale support.